SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences informs about press release

03 Oct 2022 Evaluate
Zydus Lifesciences has informed that it enclosed a copy of press release dated October 3, 2022 titled - Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1154.25 -5.60 (-0.48%)
10-Jul-2026 11:40 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1939.95
Dr. Reddys Labs. 1243.00
Cipla 1451.45
Zydus Lifesciences 1154.25
Lupin 2510.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: